Formycon at the mwb Research Roundtable

With numerous approvals, new commercialization partnerships, and product launches in various regions of the world, Formycon achieved important milestones in the first half of the year and consistently advanced its corporate development. We expect further significant operational and commercial progress in the coming months.

Although structural challenges regarding access to biosimilars continue to exist in specific markets, the global biosimilar business continues to grow dynamically and offers tremendous potential: for better patient care worldwide, for relieving the burden on healthcare systems, and for a company highly specialized in biosimilars such as Formycon.

At the mwb Research Roundtable, Dr. Stefan Glombitza (CEO), Enno Spillner (CFO), and Dr. Andreas Seidl (CSO) discuss these developments and answer participants’ questions. The Roundtable is in German.